MIT and India to Create Health Science and Technology Institute (India)
This article was originally published in PharmAsia News
MIT and the government of India's Department of Biotechnology has launched a partnership that will result in the creation of a new Translational Health Science and Technology Institute (THSTI) in India. This new institute, which will be modeled after the Harvard-MIT Division of Health Sciences and Technology (HST), will include faculty from multiple disciplines and professions, offer degrees through multidisciplinary programs, and develop strong ties with other institutions. Funded by the Indian government, the Indian HST will be a multidisciplinary, multiprofessional research and training center that is highly interconnected with regional centers of excellence. The institute will increase India's capacity for translating scientific and technological advancements into medical innovations that have the potential to improve healthcare both in India and around the world. To foster a culture of innovation in THSTI, HST will help recruit and train new THSTI faculty members. Each year starting in September 2008 and continuing until 2011, four recruited THSTI faculty fellows will join the HST faculty. These faculty fellows will train at HST for two years. During their stay they will develop translational research programs, design courses and curricula for THSTI, and develop close relationships with HST faculty and students. (Click here for more
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.